NKMAX CO., Ltd.

Equities

A182400

KR7182400002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 04:30:00 25/03/2024 am IST			5-day change	1st Jan Change
2,020 ^KRW	+9.54%		-.--%	-67.58%

17/04	NKMAX CO., Ltd. cancelled the transaction announced on October 20, 2023	CI
16/04	NKMAX CO., Ltd.(KOSDAQ:A182400) dropped from S&P Global BMI Index	CI

NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023

April 05, 2024 at 02:16 pm IST

NKMAX CO., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net income was KRW 5,261.22 million compared to net loss of KRW 53,504.73 million a year ago. Basic earnings per share from continuing operations was KRW 65 compared to basic loss per share from continuing operations of KRW 676 a year ago.

Diluted earnings per share from continuing operations was KRW 60. Basic earnings per share was KRW 65 compared to basic loss per share of KRW 676 a year ago. Diluted earnings per share was KRW 60.

Latest news about NKMAX CO., Ltd.

NKMAX CO., Ltd. cancelled the transaction announced on October 20, 2023	17/04	CI
NKMAX CO., Ltd.(KOSDAQ:A182400) dropped from S&P Global BMI Index	16/04	CI
NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/04	CI
NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 13.39999704 billion in funding	20/23/20	CI
NKMAX CO., Ltd. announced that it has received KRW 7.5 billion in funding	13/23/13	CI
NKMAX CO., Ltd. announced that it has received KRW 8.5 billion in funding	12/23/12	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 7.5 billion in funding	11/23/11	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 8.5 billion in funding	08/23/08	CI
NKMAX CO., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
NKMAX CO., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
NKMAX CO., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
NKMAX CO., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
NKMAX CO., Ltd. announced that it has received KRW 36 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Meritz Securities Co., Ltd., Meritz Capital Co., Ltd., Investment Arm	15/22/15	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 36 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Meritz Securities Co., Ltd., Meritz Capital Co., Ltd., Investment Arm	07/22/07	CI
NKMAX CO., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	21/22/21	CI
NKMAX CO., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/21/15	CI
NKMAX CO., Ltd. announced that it has received KRW 21.40019775 billion in funding	25/21/25	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 21.40019775 billion in funding	08/21/08	CI
NKMAX CO., Ltd. announced that it has received KRW 29.9999702 billion in funding from a group of investors	03/20/03	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 29.9999702 billion in funding from a group of investors	26/20/26	CI
NKMAX CO., Ltd. announced that it has received KRW 20 billion in funding from SV Investment Corp., Nongshim Capital Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, Bir Publishing Co., Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment Corp., Investment Arm, and other investors	27/20/27	CI
NKMAX CO., Ltd. announced that it expects to receive KRW 20 billion in funding from SV Investment Corp., Nongshim Capital Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, Bir Publishing Co., Ltd, NH Investment & Securities Co., Ltd., Shinhan Investment Corp., Investment Arm, and other investors	25/20/25	CI

Chart NKMAX CO., Ltd.

Duration

Period

More charts

Company Profile

NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NKMAX CO., LTD.	-67.58%	128M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs